Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
September 27 2021 - 4:01PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will report the results from its
12-week Phase 1 clinical trial of ALT-801 in overweight and obese
subjects in a pre-market press release and webcast to be held on
Tuesday, September 28, 2021.
Altimmune management will host a conference call
and webcast with a slide presentation beginning at 8:30 am E.T.
Following the conclusion of the call, the webcast will be available
for replay on the Investor Relations page of the Company’s website
at www.altimmune.com. The company has used, and intends to continue
to use, the IR portion of its website as a means of disclosing
material non-public information and for complying with disclosure
obligations under Regulation FD.
Conference Call Information:
Date: |
Tuesday, September 28 |
Time: |
8:30 am Eastern Time |
Domestic Dial-in: |
(844) 615-6509 |
International Dial-in: |
(918) 922-3148 |
Conference ID: |
3792068 |
Webcast: |
https://edge.media-server.com/mmc/p/ojyxaxpp |
About AltimmuneAltimmune is a
clinical stage biopharmaceutical company focused on developing
treatments for obesity and liver diseases. Our pipeline includes
next generation peptide therapeutics for obesity, NASH (ALT-801),
and chronic hepatitis B (HepTcell™). For more information on
Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor and Media Contact:Will BrownChief
Financial OfficerPhone: 240-654-1450wbrown@altimmune.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024